百心安-B早盘大涨逾31% 国家药监局批准IBERIS®RDN系统注册

新浪港股
27 Feb
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  百心安-B(02185)早盘大涨超31%,截至发稿,股价上涨30.53%,现报2.48港元,成交额331.97万港元。

  百心安公布,2月26日,公司附属公司上海安通医疗科技有限公司研发的Iberis®多极肾动脉射频消融系统(包括一次性使用多极肾动脉射频消融导管及肾动脉射频消融仪)(Iberis®RDN系统),已获中国国家药品监督管理局批准,用于辅助治疗难治性高血压及药物不耐受的高血压患者。

  德邦证券此前研报指出,Iberis 为全球唯一可以提供两种介入方式的肾动脉消融产品,且具备较细的导管鞘尺寸,有望凭借先发优势和强有力的产品性能迅速抢占市场。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10